This service is more advanced with JavaScript available, learn more at http://activatejavascript.org

Reactions Weekly

March 2018, Volume 1695, Issue 1, pp 76–76 | Cite as

Blinatumomab/protein tyrosine kinase inhibitors

Headache and ulnar neuropathy: 2 case reports

Case report

First Online: 31 March 2018

26 Downloads

This is a preview of subscription content, to check access

Reference

Sokolov AN, et al. Blinatumomab + tyrosine kinase inhibitors with no chemotherapy in BCR-ABL-positive or ikzf1-deleted or FLT3-ITD-positive relapsed/refractory acute lymphoblastic leukemia patients: High molecular remission rate and toxicity profile. Blood 130 (Suppl. 1): Dec 2017. Available from: URL: http://www.bloodjournal.org/content/130/Suppl_1/3884 -Russia

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

About this article

Cite this article as:: Reactions Weekly (2018) 1695: 76. https://doi.org/10.1007/s40278-018-43903-2

DOI https://doi.org/10.1007/s40278-018-43903-2
Publisher Name Springer International Publishing
Print ISSN 0114-9954
Online ISSN 1179-2051

Published in cooperation with
Adis

Personalised recommendations